Therapeutic area intelligence for Women's Health with 25 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 25
Catalysts: 0
Companies: 9

Companies

Annora Pharma →

AstraZeneca →

Breckenridge Pharma →

Breckenridge Pharmaceutical →

competing pharma companies →

Lupin →

Novast Labs →

Teva →

women's health pharma companies →

Assets

Recent signals(25)

RegulatoryAugust 3, 2026

Lupin's ANDA201446 for Levonorgestrel Receives FDA AP Status

Lupin's ANDA201446 for Levonorgestrel has been granted Abbreviated Approval (AP) status by the FDA.

ClinicalJuly 29, 2026

AstraZeneca's Study on AZD6234 and AZD9550 Impact on Oral Contraceptive Pharmacokinetics

AstraZeneca is conducting a study to evaluate the pharmacokinetics of ethinyl estradiol/levonorgestrel when administered with AZD6234 and AZD9550.

RegulatoryJuly 28, 2026

FDA Accepts Supplement Application for Estradiol and Norethindrone Acetate

The FDA has accepted the supplemental application ANDA078324 for Estradiol and Norethindrone Acetate submitted by Breckenridge Pharmaceutical.

RegulatoryJuly 23, 2026

FDA Approval Update for Norethindrone Acetate and Ethinyl Estradiol

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for a combination product containing Norethindrone Acetate and Ethinyl Estradiol.

ClinicalJuly 22, 2026

Study on Focal Shock Wave Therapy for Vulvodynia Shows Promise

A retrospective observational study is evaluating the effectiveness of a four-session focal shock wave therapy protocol for vulvodynia.

RegulatoryJuly 20, 2026

FDA Grants Approval for Carboprost Tromethamine ANDA219529

The FDA has granted approval for the ANDA219529 application for Carboprost Tromethamine submitted by Somerset TherapS LLC.

ClinicalJuly 20, 2026

Study on Mental Health Outcomes Post-Pregnancy Loss in Denmark

A study is underway to evaluate the mental health impacts of participating in the COPL cohort versus standard care after pregnancy loss.

RegulatoryJuly 18, 2026

FDA Accepts Supplement for ENDOMETRIN by Ferring

The FDA has accepted a supplemental application for ENDOMETRIN, a progesterone-based therapy.

RegulatoryJuly 16, 2026

FDA Grants AP Status for ELINEST ANDA091105 by Novast Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for ELINEST submitted by Novast Labs.

StrategyJuly 13, 2026

Study on Genetic Factors Influencing Emergency Contraceptive Efficacy

A study is investigating genetic differences that may affect the efficacy of oral emergency contraception.

RegulatoryJuly 12, 2026

Lupin's ANDA201446 for Levonorgestrel Receives Standard Review Status

Lupin's ANDA201446 for Levonorgestrel has been submitted and is currently under standard review by the FDA.

RegulatoryJuly 12, 2026

FDA Grants AP Status for Desogestrel and Ethinyl Estradiol ANDA219670

The FDA has granted Abbreviated Approval (AP) status for ANDA219670, a combination of Desogestrel and Ethinyl Estradiol.

StrategyJuly 5, 2026

FDA Approves ANDA078324 for Estradiol and Norethindrone Acetate

The FDA has granted approval for ANDA078324, a generic formulation of estradiol and norethindrone acetate.

ClinicalJuly 2, 2026

Estrogen Fluctuations Linked to Increased Depression in Postmenopausal Women

Estrogen fluctuations during menopause significantly increase the risk of depression and anxiety in women.

RegulatoryJuly 1, 2026

FDA Grants AP Status for Levonorgestrel and Ethinyl Estradiol ANDA202970

The FDA has granted Abbreviated Approval (AP) status for ANDA202970, a combination of Levonorgestrel and Ethinyl Estradiol.

RegulatoryJune 27, 2026

Teva's ANDA219324 for Junel FE Receives Approval Status from FDA

Teva Pharmaceuticals' ANDA219324 for Junel FE has received an Approval Pending (AP) status from the FDA.

RegulatoryJune 27, 2026

FDA Accepts Supplement Application for TWIRLA by AGILE

The FDA has accepted a supplemental application for TWIRLA, a contraceptive patch containing ethynyl estradiol and levonorgestrel.

RegulatoryJune 25, 2026

FDA Accepts Supplemental Application for TWIRLA

The FDA has accepted a supplemental application for TWIRLA, a contraceptive patch containing ethynyl estradiol and levonorgestrel.

ClinicalJune 25, 2026

UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment

The ENDO1000 study will collect extensive longitudinal data from 3000 individuals with endometriosis to improve diagnosis and treatment.

RegulatoryJune 23, 2026

FDA Grants AP Status for Levonorgestrel and Ethinyl Estradiol ANDA200492

The FDA has granted an Abbreviated Approval (AP) status for ANDA200492, a combination of Levonorgestrel and Ethinyl Estradiol.

CompetitiveJune 23, 2026

Lupin's ANDA091440 for Levonorgestrel and Ethinyl Estradiol Receives AP Status

Lupin Ltd's ANDA091440 for a combination of Levonorgestrel and Ethinyl Estradiol has received an Abbreviated Approval (AP) status.

RegulatoryJune 21, 2026

FDA Accepts ANDA for Doxylamine Succinate and Pyridoxine Hydrochloride

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Doxylamine Succinate and Pyridoxine Hydrochloride submitted by Pharmobedient.

ClinicalJune 20, 2026

Network meta-analysis compares minimally invasive treatments for uterine fibroids

The analysis evaluates the efficacy and safety of HIFU, RFA, MWA, and UAE against myomectomy for symptomatic uterine fibroids.

ClinicalJune 19, 2026

Study on Resistance Training's Impact on Women's Health During Menopause

A study is investigating the effects of resistance training on blood vessel health and quality of life in women starting menopause.

ClinicalJune 18, 2026

Phase II Trial Investigates Vitamin D's Impact on Menstrual Cycle Health

The inVitD Trial aims to assess the effects of vitamin D supplementation on menstrual cycle hormones in women aged 19-40.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.